Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Valeant Has Big Plans To Become A Big Pharma In Coming Year

This article was originally published in The Pink Sheet Daily

Executive Summary

The Canadian specialty pharma has been buying up companies left and right and has plans to continue in 2014, even possibly pursuing a merger of equals in an effort to more than double its market capitalization.

You may also be interested in...



Is Valeant The Fix to Salix Inventory Woes?

The Canadian pharma is willing to bet $14.5 billion that it can take care of the specialty pharma’s stocking level issues and still pull in $500 million in synergies with in the first six months.

Valeant’s One-Two Punch Sends Allergan Ducking And Weaving; Who’s Next In The Ring?

Valeant’s partnership with activist investor William Ackman to acquire Allergan for around $46 billion would be Valeant’s largest acquisition but sets the stage for a protracted fight.

Valeant’s One-Two Punch Sends Allergan Ducking And Weaving; Who’s Next In The Ring?

Valeant’s partnership with activist investor William Ackman to acquire Allergan for around $46 billion would be Valeant’s largest acquisition but sets the stage for a protracted fight.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS076478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel